Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leuprorelin depot - AbbVie/Takeda

Next Previous
X
Search
Drug Profile

Leuprorelin depot - AbbVie/Takeda

Alternative Names: A-43818; Carcinil; Enanton Depot; Enanton-Gyn; Enantone; Enantone Depot; Enantone LP; Ginecrin; Leuplin; Leuplin SR; Leuprolide acetate depot; Leuprolide acetate for depot suspension; Leuprolide depot; leuprorelide for depot suspension; Leuprorelin acetate depot; Leuprorelin Acetate Depot 3M; Lucrin; Lucrin Depot; Lupron Depot; Lupron Depot-PED; Procren Depot; Procrin; Prostap SR; TAP-144-SR; Trenantone-Gyn

Latest Information Update: 27 Dec 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer AbbVie; Norwood Abbey; Takeda
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - X-linked bulbo-spinal atrophy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Menorrhagia; Precocious puberty; Prostate cancer; Uterine leiomyoma
  • Discontinued Haematological disorders

Most Recent Events

  • 29 Nov 2023 AbbVie completes a phase III trials for Precocious puberty in Puerto Rico and USA (IM) (NCT03695237) (EudraCT2022-004131-61)
  • 21 Feb 2023 Leuprorelin depot is still in phase III trials for Precocious Puberty in Puerto Rico (NCT03695237)
  • 17 Feb 2021 Leuprolide Acetate is still in phase III trials for Precocious puberty in Puerto Rico and USA (IM)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top